In summary, besides PD-1, which is an already known target for immunotherapy, our results suggest that expression of CD85j, CD45 and CD48 on NK cells from ccRCC patients constitute potential biomarkers and they might constitute candidates for therapeutic intervention that deserve further investigation. The gene discussed is LILRB1; the disease is nonpapillary renal cell carcinoma.